The trading price of Galectin Therapeutics Inc (NASDAQ:GALT) floating lower at last check on current market day and closing at $1.89, -7.33% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $1.82 and $2.085. In examining the 52-week price action we see that the stock hit a 52-week high of $4.27 and a 52-week low of $1.55. Over the past month, the stock has lost -33.27% in value.
Galectin Therapeutics Inc, whose market valuation is $114.71 million at the time of this writing, is expected to release its quarterly earnings report in January. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 0 per share this quarter, however they have predicted annual earnings per share of 0 for current year and 0 for next year.
On the technical side, indicators suggest GALT has a 25% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that GALT’s price is currently -28.54% off the SMA20 and -28.47% off the SMA50. The RSI metric on the 14-day chart is currently showing 24.75, and weekly volatility stands at 11.82%. When measured over the past 30 days, the indicator reaches 7.81%. Galectin Therapeutics Inc (NASDAQ:GALT)’s beta value is currently sitting at 0.71, while the Average True Range indicator is currently displaying 0.20.
To see how Galectin Therapeutics Inc stock has been performing today in comparison to its peers in the industry, here are the numbers: GALT stock’s performance was -7.33% at last check in today’s session, and -1.81% in the past year.
An evaluation of the daily trading volume of Galectin Therapeutics Inc (NASDAQ:GALT) indicates that the 3-month average is 184.55K. However, this figure has increased over the past 10 days to an average of 0.43.
Currently, records show that 62.31 million of the company’s shares remain outstanding. The insiders hold 30.54% of outstanding shares, whereas institutions hold 15.67%. The stats also highlight that short interest as of 2024-10-31, stood at 5.52 million shares, resulting in a short ratio of 42.37 at that time. From this, we can conclude that short interest is 1841.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were up slightly from the previous month’s figure, which was 5.38 million. However, since the stock’s price has seen 14.16% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
